KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

Luke, JJ; Ascierto, PA; Carlino, MS; Gershenwald, JE; Grob, JJ; Hauschild, A; Kirkwood, JM; Long, GV; Mohr, P; Robert, C; Ross, M; Scolyer, RA; Yoon, CH; Poklepovic, A; Rutkowski, P; Anderson, JR; Ahsan, S; Ibrahim, N; Eggermont, AMM

Luke, JJ (corresponding author), Univ Pittsburgh, Canc Immunotherapeut Ctr, UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA.

FUTURE ONCOLOGY, 2020; 16 (3): 4429